PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

heparin Side Effects

The reactions most often reported to the FDA for heparin (also sold as Heparin Sodium), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

12,966
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of heparin come from 12,966 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 12,966 reports to the FDA Adverse Event Reporting System (FAERS) for heparin (Heparin Sodium): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

12,966

Reports Mentioning Death

2,519

19.4% of reports — not proof the medicine caused the death

Hospitalizations

5,169

39.9% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

HEPARIN-INDUCED THROMBOCYTOPENIA
1,207
NAUSEA
708
DRUG HYPERSENSITIVITY
603
VOMITING
572
HYPOTENSION
547
DYSPNOEA
519
PYREXIA
465
THROMBOCYTOPENIA
458
PULMONARY EMBOLISM
457
SEPSIS
452
ABDOMINAL PAIN
449
ANAEMIA
440
THROMBOSIS
406
CONDITION AGGRAVATED
368
DEATH
364
DIARRHOEA
361
CONSTIPATION
355
PNEUMONIA
350

Who Reports Side Effects

Gender Distribution

Female 4,912 (45%)
Male 5,808 (53%)
Unknown 148

Age Distribution

0-17 703 (8%)
18-44 1,433 (15%)
45-64 2,924 (31%)
65-74 2,249 (24%)
75+ 2,053 (22%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 2,519 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 364
SEPSIS 339
MULTIPLE ORGAN DYSFUNCTION SYNDROME 309
VOMITING 279
NAUSEA 277
GENERAL PHYSICAL HEALTH DETERIORATION 266
HEPARIN-INDUCED THROMBOCYTOPENIA 254
CARDIOGENIC SHOCK 240
ABDOMINAL PAIN 239
HYPONATRAEMIA 233
CONSTIPATION 227
STRESS 227
ASCITES 224
PULMONARY EMBOLISM 216
ABDOMINAL DISTENSION 215
APPENDICITIS 209
APPENDICOLITH 206
VENTRICULAR FIBRILLATION 198
CONDITION AGGRAVATED 197

Reactions in Hospitalization Reports

Top reactions in 5,169 reports where hospitalization was an outcome.

Reaction Reports
HEPARIN-INDUCED THROMBOCYTOPENIA 565
PYREXIA 329
NAUSEA 308
ANAEMIA 294
VOMITING 287
PULMONARY EMBOLISM 277
DYSPNOEA 269
SEPSIS 256
PNEUMONIA 253
CONDITION AGGRAVATED 230
DIARRHOEA 220
THROMBOSIS 213
ABDOMINAL PAIN 212
THROMBOCYTOPENIA 212
FEBRILE NEUTROPENIA 204
HYPOTENSION 201
CONSTIPATION 190
HAEMOGLOBIN DECREASED 189

Compare heparin vs apixaban →

What the FAERS Data Reveals About heparin Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 12,966 voluntary reports linked to heparin and its brand equivalents (Heparin Sodium), spanning 2004 through 2025. Of those, 2,519 (19.4%) listed death as an outcome and 5,169 (39.9%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 45% were female and 53% male; age distribution skews toward 45-64, with 2,924 reports in that bracket. The single most reported reaction is heparin-induced thrombocytopenia with 1,207 submissions, followed by nausea and drug hypersensitivity.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.